Vertex Pharmaceut…
USUSDVertex Pharmaceuticals Inc (US:VRTX) — Biotechnology: Pharmaceutical Preparations. Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 3. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie įmonę
- Svetainė
- vrtx.com
- Sektorius
- Health Care · Biotechnology: Pharmaceutical Preparations
- Būstinė
- Boston, United States
- Generalinis direktorius
- Reshma Kewalramani
- Darbuotojai
- 6 400
- Įkurta
- 1989
- Apyvartoje esančios akcijos
- 253.46 mln. 2026-07-31 duomenimis
- Laisvai apyvartinės akcijos
- 252.69 mln.
- Rinkos kapitalizacija
- 128.36 mlrd. USD
- Insaideriai
- 0.21%
- Instituciniai investuotojai
- 97.94%
- Šaka (SIC)
- Pharmaceutical Preparations
- Teisinė forma
- ZJTK
- ISIN
- US92532F1003
- LEI
- 54930015RAQRRZ5ZGJ91
Aprašymas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Dividendai
Dividendų išmokų nerasta (patikrinta 06.10.2026). Įmonė greičiausiai nemoka dividendų.
Didžiausi akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos data |
|---|---|---|---|
| Capital World Investors | 10.29% | 26.12 mln. | 2026-06-30 |
| Blackrock Inc. | 9.5% | 24.11 mln. | 2026-06-30 |
| Capital Research Global… | 7.68% | 19.49 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 16.58 mln. | 2026-06-30 |
| Growth Fund of America | 4.94% | 12.54 mln. | 2026-06-30 |
| State Street Corporation | 4.68% | 11.87 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 8.06 mln. | 2026-06-30 |
| Invesco Ltd. | 3.17% | 8.04 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 6.58 mln. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.57% | 6.52 mln. | 2026-06-30 |
| Investment Co of America | 2.47% | 6.27 mln. | 2026-06-30 |
| Geode Capital Management… | 2.37% | 6.02 mln. | 2026-06-30 |
| AMERICAN BALANCED FUND | 2.19% | 5.56 mln. | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 5.46 mln. | 2026-08-31 |
| Vanguard Portfolio Manag… | 1.92% | 4.88 mln. | 2026-06-30 |
| Capital International In… | 1.85% | 4.7 mln. | 2026-06-30 |
| Amcap Fund | 1.83% | 4.65 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.33% | 3.38 mln. | 2026-08-31 |
| NEW PERSPECTIVE FUND | 1.33% | 3.37 mln. | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 3.28 mln. | 2026-07-31 |
| ARBUCKLE STUART A (Chief… | ≈0.04% | 100 751 | 2025-05-13 |
| KEWALRAMANI RESHMA (Chie… | ≈0.04% | 98 278 | 2026-02-27 |
| SACHDEV AMIT (Officer) | ≈0.03% | 74 031 | 2026-07-21 |
| TATSIS OURANIA (Officer) | ≈0.02% | 53 572 | 2026-07-21 |
| WAGNER CHARLES F JR (Chi… | ≈0.02% | 48 786 | 2026-02-17 |
| SACHS BRUCE I (Director) | ≈0.02% | 45 000 | 2025-08-06 |
| LEIDEN JEFFREY M (Office… | ≈0.02% | 38 784 | 2026-02-17 |
| ALTSHULER DAVID (Officer… | ≈0.01% | 34 477 | 2026-01-22 |
| LIU JOY (Officer) | ≈0.01% | 19 131 | 2026-07-01 |
| ATKINSON EDWARD MORROW I… | ≈0.01% | 18 432 | 2026-02-25 |
Reguliuotojo įvykiai
| Data | Reguliuotojas | Įvykis | Išsamiau |
|---|---|---|---|
| 2026-10-02 | ESMA | оновлення даних інструмента | ISIN, майданчик HAND |
